13F-HR filed by Stonepine Capital Management, LLC
Stonepine Capital Management, LLC filed this 13F-HR for the quarter ended 2019-12-31, filed 2020-02-13, with 23 holding rows worth $143,457,000.
- Accession
- 0001567619-20-003323
- Filer
- CIK 1440771
- Filed
- 2020-02-13
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2019
A holdings report, 23 entries on the cover page, a total value of $143,457,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $143,457,000 with VALUE read as thousands by filing date, 13F file number 028-17175. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| AMARIN CORP PLC | 023111206 | SPONS ADR NEW | 1,551,300 | $33,260,000 | thousands by filing date | |
| IVERIC BIO INC | 46583P102 | COM | 3,000,000 | $25,740,000 | thousands by filing date | |
| AFFIMED N V | N01045108 | COM | 4,010,155 | $10,988,000 | thousands by filing date | |
| OXFORD IMMUNOTEC GLOBAL PLC | G6855A103 | ORD SHS | 630,862 | $10,472,000 | thousands by filing date | |
| ADAMAS PHARMACEUTICALS INC | 00548A106 | COM | 2,241,239 | $8,494,000 | thousands by filing date | |
| NEOS THERAPEUTICS INC | 64052L106 | COM | 4,858,889 | $7,337,000 | thousands by filing date | |
| CTI BIOPHARMA CORP | 12648L601 | COM | 3,755,000 | $5,933,000 | thousands by filing date | |
| XOMA ROYALTY CORPORATION | 98419J206 | COMMON STOCK | 200,667 | $5,478,000 | thousands by filing date | |
| OPIANT PHARMACEUTICALS INC | 683750103 | COM | 334,272 | $4,814,000 | thousands by filing date | |
| EVOLUS INC | 30052C107 | COM | 394,890 | $4,806,000 | thousands by filing date | |
| APOLLO ENDOSURGERY INC | 03767D108 | COM | 1,651,333 | $4,706,000 | thousands by filing date | |
| CUMBERLAND PHARMACEUTICALS I | 230770109 | COM | 896,170 | $4,615,000 | thousands by filing date | |
| HTG MOLECULAR DIAGNOSTICS IN | 40434H104 | COM | 4,758,426 | $3,340,000 | thousands by filing date | |
| AEGERION PHARMACEUTICALS INC | 00767EAC6 | NOTE 5.000% 4/0 | 2,993,334 | $2,844,000 | thousands by filing date | |
| NOVELION THERAPEUTICS INC | 67001K202 | COM NEW | 3,909,207 | $2,759,000 | thousands by filing date | |
| APTEVO THERAPEUTICS INC | 03835L108 | COM | 4,179,131 | $2,735,000 | thousands by filing date | |
| CATALYST BIOSCIENCES INC | 14888D208 | COM | 307,287 | $2,093,000 | thousands by filing date | |
| CHIASMA INC | 16706W102 | COM | 183,660 | $911,000 | thousands by filing date | |
| STRONGBRIDGE BIOPHARMA PLC | G85347105 | SHS USD | 431,853 | $903,000 | thousands by filing date | |
| SCYNEXIS INC COM NEW | 811292101 | Common Stock | 609,384 | $555,000 | thousands by filing date | |
| INTERPACE BIOSCIENCES INC | 46062X303 | COM | 943,851 | $472,000 | thousands by filing date | |
| RESTORBIO INC | 76133L103 | COM | 81,772 | $122,000 | thousands by filing date | |
| ACER THERAPEUTICS INC | 00444P108 | CMN | 20,000 | $80,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001567619-20-003323 | this filing | 2020-02-13 | acceptance time not in the bulk data set |